CYTK Cytokinetics, Incorporated
$73.77▲ +0.20%
Healthcare
Other
After hours
$73.77▲ +0.00%
Sep 11, 7:30 PM ET
Volume 1.72M
Avg Volume (10D) 1.96M
Key Metrics & Fundamentals
Market Cap
$10.26B
P/E Ratio
–
Div Yield
–%
52W Range
47.22 - 88.31
% vs 50 MA
-5.82%
% vs 200 MA
5.46%
RSI-14
45.1
MACD Histogram
+0.0700
Beta (1Y vs SPY)
0.90
Free Cash Flow
-$164.17M
Gross Rev
$28.62M
Gross Profit
$23.03M
EBITDA
-$159.20M
COGS
$5.59M
Operating Exp
$202.20M
Operating Income
-$179.17M
EBIT
-$179.17M
Pretax Income
-$198.76M
Net Income
-$198.76M
EPS (Diluted)
-1.50
Price & Volume History
Loading chart…
Recent News
Cytokinetics Has Advantage in Bristol-Myers Squibb Patent Dispute, RBC Says
MT Newswires · Sep 10, 2026 4:08 PM
Could Aficamten Give Cytokinetics the First Approved nHCM Treatment?
Insider Monkey · Sep 8, 2026 1:05 AM
Cytokinetics to Participate in September Investor Conferences
GlobeNewswire · Sep 2, 2026 8:00 PM
Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?
Zacks · Sep 2, 2026 6:30 PM
Cytokinetics Insider Sold Shares Worth $357,400, According to a Recent SEC Filing
MT Newswires · Sep 1, 2026 9:01 PM
Cytokinetics (CYTK) Presents New Phase 3 Data, Is It Still 34% Undervalued?
Simply Wall St. · Sep 1, 2026 1:08 PM
Cytokinetics (CYTK) Reaches A Phase 3 First In Non Obstructive HCM
Simply Wall St. · Sep 1, 2026 5:05 AM
Cytokinetics Insider Sold Shares Worth $702,400, According to a Recent SEC Filing
MT Newswires · Aug 31, 2026 9:03 PM
Jefferies starts biopharma firm Braveheart at Buy after IPO
Investing.com · Aug 31, 2026 11:00 AM
ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy
BioPharma Dive · Aug 31, 2026 10:49 AM
Financial Overview - Income Statement
Quarterly
Jun 2026
See CYTK's money flow as a full page
Social Sentiment
No Reddit posts found for CYTK.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.